Clinical Trial Update: Expanded Access of Pimavanserin for Patients With PD Psychosis

View source ↗

Summary

Expanded access for Pimavanserin (Nuplazid) in Parkinson's disease psychosis is noted, with the status indicating approval for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• Nuplazid (Pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson's Disease Psychosis | Status: APPROVED_FOR_MARKETING